semaj83/ctmatch_classification huggingface dataset:
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HPV Infection Cervical Cancer CIN2 confirmed by biopsy, age between 18 and 39 years satisfactory colposcopy identifying the junction and the lesion affiliated person or beneficiary of a social security scheme having given their oral agreement and authorization to the processing of their data  Pregnancy in progress history of conization atypical or atypical glandular cells or cancer incidentally discovered during smear prophylactic vaccination against HPV active systemic infection requiring treatment, history of HIV infection, congenital or acquired immunodepression long-term treatment with corticosteroids or immunosuppressants, placement under safeguard of justice non-compliance with protocol requirements, in particular a supposed lack of compliance with long-term follow-up
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chiasmal; Lesion Prechiasmal; Lesion Adult population (18 years and older), admitted to The Ottawa Hospital (TOH)-Civic Campus for a chiasmal or pre-chiasmal lesion, undergoing first time minimally invasive endoscopic skull base surgery Patient able to personally sign and date the informed consent document Patients will be selected based on the surgeon's determination that: 1. The visual system will be at risk of iatrogenic injury 2. The intraoperative FVEPs monitoring could rapidly detect this injury AND 3. Corrective measures could be taken during surgery to reverse it  patients having a pre-existent retinal disease, cardiac pacemaker contraindication for total intravenous anaesthesia (TIVA) unable to complete required pre and post-operative visual assessment or unable to complete their post-operative follow-up visits at TOH-Civic Campus anticipated goggle movement related to reflection of the frontal skin flap preoperative visual deficits (e.g., profound deficits in visual acuity or dense visual field loss)
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 21.0-65.0,  Cervical Cancer Female of at least 21 years of age and not over 65 presenting who need routine cervical cancer screening per national guidelines  prior history of cervical cancer or a positive Pap smear, have had a total hysterectomy (removal of uterus and cervix), or currently enrolled in any other cancer prevention study
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Perineum; Injury primiparous or multiparous women who have never given birth vaginally term patients (after 37 weeks of amenorrhea) patients delivering a fetus in cephalic presentation patients speaking and understanding French  patients suspected of having a fetal macrosomy (greater than the 97th percentile) on the last ultrasound patients with twin pregnancies excised patients patient who has made an acupuncture preparation during pregnancy patients with fetal death in utero patients requiring medical termination of pregnancy
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Head and Neck Cancer Squamous Cell Carcinoma of Head and Neck Histologically proven, recurrent or metastatic SCCHN not curable by local therapy No prior systemic therapy for SCCHN in the recurrent or metastatic setting (with the exception of systemic therapy completed > 6 months prior of given as part of multimodal treatment for locally advanced disease) Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx At least one radiographically measurable lesion HPV test results available (positive and negative eligible) ECOG Performance status of 0 or 1 Adequate end organ function Positive PD-L1 expression level (CPS ≥ 1%)  Disease suitable for local therapy administered with curative intent Progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced SCCHN Radiation or other non-systemic therapy within 2 weeks of first dose of study drug Diagnosis of immunodeficiency, or use of immunosuppresive therapy within 14 days of first dose of study drug
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Healthy Diet Latina immigrant Resident of selected randomization unit (place of residence) At least one HPV unvaccinated daughter between the ages of 9 and 12
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 30.0-49.0,  Cervical Dysplasia Must be 30-49 years old 2. High-grade squamous intraepithelial lesion of the cervix (CIN 2/3), confirmed on histology 3. Eligible for cryotherapy based on size of lesion (occupies <75% of cervix) and fully visible on colposcopy or visual inspection with acetic acid (VIA) 4. Willing and able to provide consent  Menopausal 2. History of hysterectomy 3. Known HIV+ or active cervical infections 4. Lesion occupies >75% of cervix and/or extends into the endo cervical canal 5. Pregnancy
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Cervix, Dysplasia HPV Infection HPV Vaccine Cervix Lesion Women older than 18 years who received excisional therapy due to HSIL /CIN injury confirmed histologically Women who sign informed consent Patients with negative results in the first post-surgery control Patients who have received HPV vaccination and provide vaccination card  Women who do not wish or cannot give their informed consent and / or do not comply with the requirements of the study Patients treated by an indication other than HSIL/CIN Patients under immunosuppression conditions
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 25.0-999.0,  HSIL, High Grade Squamous Intraepithelial Lesions Recurrence Diagnosis of HSIL/CIN2-3 by colposcopy guided biopsy (CGB) or endocervical curettage (ECC) in the 3 months prior to LEEP and/or confirmation of HSIL/CIN2-3 in the pathologic study of the surgical specimen  Patients with acquired or congenital immunosuppression Patients undergoing chronic immunosuppressive treatments, prior treatment with LEEP Patients in whom HSIL/CIN2-3 was not histologically confirmed
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 25.0-999.0,  HPV Infection Lesion Cervix Woman over 25 years, whether or not they have been vaccinated against HPV. 2. Able to read and understand the Patient Information Sheet and the Informed Consent form and accept the participation in the study by signing the Informed Consent form. 3. Patient who comes to a visit with a routine cytological result of ASCUS or LSIL and HPV-positive test, of at most 3 months prior to the start of treatment with Papilocare®. 4. Patient who, under that situation, undergoes a colposcopy and has a concordant result with cytology. 5. Patient who has been prescribed treatment with Papilocare® by medical decision prior to their participation in the study  Any situation / alteration / pathology, gynecological or not, which, in medical judgment, does not advise or contraindicate the use of Papilocare®. 2. Women of childbearing age who do not use effective contraceptive methods, pregnant women, suspected pregnancy, desire for the same within the next 6 months or during breastfeeding. 3. Participation in any one clinical trial at present or in the 4 weeks prior to in the study. 4. Any planned surgery that precludes correct compliance with the guideline. 5. Known allergies to any of the components of Papilocare®
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 30.0-65.0,  HPV Infection Lesion Cervix Woman between the ages of 30 and 65 (both included). 2. Able to read and understand the Patient Information Sheet and informed consent 3. Accept participation in the study and sign the Informed Consent. 4. Cytological result of ASC-US or LSIL, with concordant colposcopic image, at most 3 months before the selection visit. It is considered concordant with ASCUS and LSIL, a colposcopic result of normality, of non-specific findings or of type 1 changes. 5. Positive HPV according to cobas 4800 technique (high-risk HPV) carried out in a selection visit (or positive available at most 3 months prior to the baseline visit). 6. Women vaccinated and not vaccinated against HPV. 7. Is able, at the discretion of the researcher, to comply with the requirements of the study and without impediments to follow the instructions and assessments throughout it  Clinically relevant alterations of the immune system or any other autoimmune disease or in treatment with immunosuppressants. 2. Other cytological results other than those provided for in the criteria. 3. Baseline LSIL biopsies with CIN-3. 4. Abnormal undiagnosed genital bleeding (during the 6 months prior to the selection visit) 5. Other symptomatic vulvovaginal infections. 6. Surgical cervical excision in the last year or total hysterectomy. 7. Previous history of gynecological cancer. 8. Participation in any other clinical trial at present or in the 4 weeks prior to of the study. 9. Any planned surgery that precludes correct compliance with the guideline. 10. Use of vaginal contraceptives or other vaginal hormonal treatments. 11. Contraindications to the use of Papilocare® gel or known allergies to any of its components. 12. Women of childbearing age who do not use effective contraceptive methods, pregnant women, with suspected pregnancy or breastfeeding
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Chiari Malformation Type I Proprioceptive Disorders Coordination and Balance Disturbances Syringomyelia Basilar Invagination Exercise Addiction Atlanto-Axial Subluxation The study was planned to involve at least 20 individuals with CM Type 1 who were not surgical indications in the 18-65 age range  Motor type defect due to CM Type 1 Presence of primary neurological disease other than CM Type 1, severe cognitive impairment (> 24 from the Mini Mental State Assessment) peripheral vestibular problem and history of orthopedic surgery patients who had musculoskeletal problems in the last 6 months and who received physiotherapy rehabilitation program in the last 6 months
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 22.0-65.0,  Cervical Cancer Female Age ≥ 22 years and ≤ 65 Referred for colposcopy, following abnormal cervical cytology Participant provides signed informed consent  Currently pregnant (through six weeks postpartum) or nursing Currently menstruating Previous hysterectomy Currently has intrauterine device (IUD) Cervical biopsy or therapeutic procedure since the referral cervical cytology Diagnosed with diseases that may influence the color of the tissue, e.g., hepatitis, polycythemia vera Known human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS) (Applicable to training stage only) A known latex allergy Psychological instability, inappropriate attitude or motivation Cervical cytology tests within the prior seven days
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Behavioral Economics Primary Health Care Health Maintenance Diabetes Colorectal Cancer Screening Cervical Cancer Screening Chlamydia Screening HPV Screening Primary care physicians within the UCLA Health Department of Medicine Primary Care Network and with the following specialties: Internal Medicine, Geriatrics, Internal Medicine/Pediatrics, or Family Medicine Clinical full-time employee level (FTE) of ≥ 40% at the beginning of the intervention period Eligible to receive performance-based financial incentive as determined by the Department of Medicine Panel size >50 patients before the first intervention email was sent Patients, with at least one Health Maintenance topic open before or during at least one visit that takes place with a physician enrolled in the study between November 5, 2019 and March 3, 2020  Not a primary care physician within the UCLA Health Department of Medicine Primary Care Network Not a primary care physician with the following specialties: Internal Medicine, Geriatrics, Internal Medicine/Pediatrics, or Family Medicine Clinical FTE < 40% Not eligible to receive performance-based financial incentive as determined by the Department of Medicine Panel size greater than 50 patients before the first intervention email was sent Patients that are not seen by a provider enrolled in the study period Patients seen by physician in the study with no Health Maintenance topics open before or during any visit that takes place between November 5, 2019 and March 3, 2020
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Dysplasia Cervical Disease Cervical Lesion Cervix Cancer Cervical Cancer Cervical Neoplasm Referred for colposcopy due to a cervical smear test of Atypical Squamous Cells of Undetermined Significance (ASCUS), low-grade intraepithelial lesion (LSIL), atypical squamous cells, cannot a high-grade lesion (ASC-H), high-grade intraepithelial lesion (HSIL), Atypical glandular cells (ACG) or carcinoma in situ (CIS) Referred for colposcopy due to follow-up of previously diagnosed CIN (If there has been a minimum of 6 months since previous cervical biopsies)  Cervical biopsies taken within the last 6 months Previous cone procedure Currently pregnant Pregnant within the last 6 months
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 15.0-45.0,  Pregnancy Related Age 15 to 45 years Self-identified as Black/African American Pregnant or recently gave birth (less than 6 months post-delivery) English speaking  Cognitive impairment Incarceration Adults unable to consent
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Neoplasm Cervix HIV-uninfected and infected women (without current AIDS-defining illness) Presence of a cervix Biopsy-proven LSIL disease or recently treated HSIL disease Adherence to combined anti-retrovirals (cART) if HIV infected On continuous antiretrovirals with a cluster of differentiation 4 (CD4) count >200 cells/ml with sustained undetectable viral load for at least 3 months (only for HIV-positive participants) On reliable birth control: combined oral contraceptive pills (OCP), long-acting reversible contraception (LARC), bilateral tubal ligation (BTL) or Depo-Provera (birth control shot) Willing to conform to the study requirements Reliable follow-up and contact information No risk factors for HSIL or microinvasive disease (no colposcopic features of microinvasion, adequate colposcopy and negative endocervical curettage) For women with HSIL only, LEEP completed within 6 weeks preceding initial encounter with study staff and adequate wound healing  Untreated HSIL or invasive features on colposcopy and the biopsy specimen Not adherent to anti-retroviral therapy (cART) (HIV infected participants) CD4 count =<200 cells/ml and detectable viral load within the last 3 months (only for HIV-positive participants) Lactating and pregnant people Patient with irregular cycles (more than once a month) Not on reliable birth control Previous hysterectomy Prior diagnosis of cervical cancer, treated or untreated Inability to provide informed consent Medical condition that interferes with the conduct of the study in the investigator's opinion
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Histologically confirmed primary adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, or other histological types carcinoma of the uterine cervix. 2. Patients with Histologically confirmed stage IA1 (with lymph vascular invasion), FIGO 2018 stage IA2 to IIA2. 3. Underwent radical hysterectomy or radiochemotherapy. 4. ECOG Performance Status of 0 or 1  Life expectancy is less than 6 months 2. No prior malignancy 3. ECOG Performance Status of 2 to 5
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Cervical Dysplasia Cervical Lesion Cervix Disease Women ≥ 45 years with a positive screening test (abnormal cytology and/or persistence HPV positive) who are referred to the Department of Obstetrics and Gynecology Type 2 or 3 transformation zone (a partly or invisible transformation zone)  Type 1 transformation zone (fully visible) Current or previous diagnosis of cervical cancer Pregnancy or pregnancy wish Previously cone biopsy
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pelvic Organ Prolapse Stage II-IV pelvic organ prolapse Bothersome bulge symptoms At least 725 MET-minutes/week on International Physical Activity Questionnaire Short Form English-speaking Undergoing treatment of prolapse Surgery occurring at least 7 days from date of randomization (to allow for collection of at least 7 days of preoperative accelerometer data) Able and willing to follow up at 3 months for in-office exam  Enrollment in another research study of pelvic organ prolapse Concomitant non-urogynecologic surgery Planned further surgery in the next 3 months or anticipated treatment which would result in prolonged inactivity (such as a cancer diagnosis) 3 months postoperatively